Novartis is investing in a novel type of medicine to reduce the risk of heart disease.

Novartis investigators find genetic explanations for why some young patients relapse.

Combination of two compounds shows promise in the lab

Novartis data scientists are using super-resolution microscopy to see neurodegeneration the moment it starts.

Novartis researchers are peering deep inside knees to see if regenerated cartilage is springy like natural cartilage.

Cambridge neighbors, NIBR and Harvard, further disrupt technology. Read how their alliance is accelerating drug discovery.

A conversation with Novartis Chief Digital Officer Bertrand Bodson

Novel digital platform for clinical trial data collection could help facilitate much-needed biomedical research in lower-income countries.